• News
  • SAN DIEGO
  • BioTech

Michael Narachi joins PhRMA's board of directors

Orexigen Therapeutics Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, announced that Michael Narachi, president and CEO, has been named to the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Narachi will serve as a director for a two-year term.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Orexigen Therapeutics Inc.

Company Website

3344 North Torrey Pines Ct. Ste., 200
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
OREX
5.73
  -0.18  
- 3.05%
3,692,472,000
7.82
4.59

Orexigen Therapeutics Inc. Executive(s):

Michael Narachi

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
Subscribe Today!